Novo Nordisk A/S
NVO
$65.77
$0.921.42%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.67% | 24.86% | 27.74% | 31.76% | 34.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.67% | 24.86% | 27.74% | 31.76% | 34.73% |
| Cost of Revenue | 24.10% | 23.21% | 22.41% | 29.06% | 29.67% |
| Gross Profit | 22.41% | 25.16% | 28.74% | 32.26% | 35.68% |
| SG&A Expenses | 9.26% | 9.22% | 14.78% | 14.91% | 22.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -682.42% | -8.33% | 92.85% | 50.61% | 127.72% |
| Total Operating Expenses | 16.46% | 17.85% | 21.15% | 24.79% | 29.11% |
| Operating Income | 30.05% | 33.41% | 36.22% | 40.92% | 42.09% |
| Income Before Tax | 16.90% | 21.44% | 29.07% | 38.99% | 52.81% |
| Income Tax Expenses | 21.18% | 24.76% | 37.11% | 46.61% | 58.53% |
| Earnings from Continuing Operations | 15.82% | 20.61% | 27.14% | 37.16% | 51.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.82% | 20.61% | 27.14% | 37.16% | 51.42% |
| EBIT | 30.05% | 33.41% | 36.22% | 40.92% | 42.09% |
| EBITDA | 29.93% | 32.18% | 34.67% | 40.19% | 41.08% |
| EPS Basic | 16.43% | 21.37% | 28.09% | 38.34% | 52.90% |
| Normalized Basic EPS | 25.45% | 30.62% | 36.58% | 47.49% | 54.46% |
| EPS Diluted | 16.56% | 21.47% | 28.16% | 38.32% | 52.89% |
| Normalized Diluted EPS | 25.55% | 30.71% | 36.67% | 47.57% | 54.53% |
| Average Basic Shares Outstanding | -0.54% | -0.64% | -0.78% | -0.90% | -0.98% |
| Average Diluted Shares Outstanding | -0.62% | -0.72% | -0.85% | -0.96% | -1.02% |
| Dividend Per Share | 19.95% | 19.95% | 43.18% | 43.18% | 57.68% |
| Payout Ratio | 0.03% | 0.16% | 0.10% | 0.13% | 0.02% |